The DESTINY06 trial explores the benefit of T-DXd in breast cancer with even lower levels of HER2 expression, the ultralow group (weak membrane staining in 0 < x < 10% of tumour cells) [20]. This evidence concerns the gene ERBB2 and neoplasm.